Overview

• Novo Nordisk, a leading pharmaceutical company in weight-loss drugs, has signed research agreements with two American biotech firms, Omega Therapeutics and Cellarity.
• The deals, worth up to $1.1 billion, are part of Novo Nordisk's partnership with venture capital firm Flagship Pioneering.
• The collaboration with Omega Therapeutics aims to develop an obesity treatment that boosts metabolic activity through thermogenesis.
• The agreement with Cellarity focuses on developing a small molecule therapy for metabolic dysfunction-associated steatohepatitis (MASH), a liver inflammation caused by excess fat storage.
• Following the announcement of these deals, Novo Nordisk's shares rose more than 4%, hitting a record high of over $108.